Substance / Medication

Dalteparin sodium

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

32 trials linked to this intervention

32
Total Trials
9
Recruiting
5
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Effect of dalteparin sodium administration on IVF outcome in non-thrombophilic young women: a pilot study.
Noci Ivo, Milanini Maria Novella, Ruggiero Maria et al. · Reprod Biomed Online · 2011
PMID: 21498125RCT
Leukocytapheresis for ulcerative colitis: a comparative study of anticoagulant (nafamostat mesilate vs. dalteparin sodium) for reducing clinical complications.
Ashizuka Shinya, Nishiura Ryosuke, Ishikawa Naoto et al. · Ther Apher Dial · 2006
PMID: 16556137Observational
Assessment of the stability of dalteparin sodium in prepared syringes for up to thirty days: an in vitro study.
Laposata Michael, Johnson Stephen M · Clin Ther · 2003
PMID: 12809968Observational
Dalteparin sodium (fragmin) administration following acute infarction does not affect myocardial perfusion and function in swine.
Scheinowitz Mickey, Heled Yuval, Chouraqui Pierre et al. · Cardiovasc Drugs Ther · 2002
PMID: 12652099Observational
New Pediatric Indication for Dalteparin Sodium.
Aschenbrenner Diane S · Am J Nurs · 2019
PMID: 31567246Other
Dalteparin sodium prevents liver injury due to lipopolysaccharide in rat through suppression of tumor necrosis factor-alpha production by Kupffer cells.
Tsukada Shigeki, Enomoto Nobuyuki, Takei Yoshiyuki et al. · Alcohol Clin Exp Res · 2003
PMID: 12960499Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Dalteparin sodium (substance)
SNOMED CT
108987000
UMLS CUI
C0282471

Clinical Data

This intervention maps to 13 entities in the Healos knowledge graph.

7
Conditions
3
Biomarkers
2
Specialists
0
Symptoms
32
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.